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Abstract
Background: Adult T cell leukemia results from the malignant transformation of a CD4
+ lymphoid clone carrying
an integrated HTLV-1 provirus that has undergone several oncogenic events over a 30-60 year period of persistent
clonal expansion. Both CD4
+ and CD8
+ lymphocytes are infected in vivo; their expansion relies on CD4
+ cell cycling
and on the prevention of CD8
+ cell death. Cloned infected CD4
+ but not CD8
+ T cells from patients without
malignancy also add up nuclear and mitotic defects typical of genetic instability related to theexpression of the
virus-encoded oncogene tax. HTLV-1 expression is cancer-prone in vitro, but in vivo numerous selection forces act
to maintain T cell homeostasis and are possibly involved in clonal selection.
Results: Here we demonstrate that the HTLV-1 associated CD4
+ preleukemic phenotype and the specific patterns
of CD4
+ and CD8
+ clonal expansion are in vivo selected processes. By comparing the effects of recent (1 month)
experimental infections performed in vitro and those observed in cloned T cells from patients infected for >6-26
years, we found that in chronically HTLV-1 infected individuals, HTLV-1 positive clones are selected for tax
expression. In vivo, infected CD4
+ cells are positively selected for cell cycling whereas infected CD8
+ cells and
uninfected CD4
+ cells are negatively selected for the same processes. In contrast, the known HTLV-1-dependent
prevention of CD8
+ T cell death pertains to both in vivo and in vitro infected cells.
Conclusions: Therefore, virus-cell interactions alone are not sufficient to initiate early leukemogenesis in vivo.
Introduction
HTLV-1 is the deltaretrovirus that causes adult T-cell
leukemia/lymphoma (ATLL) [1] and inflammatory
diseases such as tropical spastic paraparesis (TSP)/
HTLV-1-associated myelopathy (HAM) [2]. In vivo,t h e
deltaretrovirus infection is a two-step process that
includes an early, transient and intense burst of horizon-
tal replicative dissemination of the virus followed by the
persistent clonal expansion of infected cells which
encompasses the remaining lifespan of infected organ-
isms [3-6]. Clonal expansion is accompanied by somatic
mutations, which are regularly detected in vivo [5,7].
HTLV-1 infects CD4
+ and CD8
+ T cells that roughly
display similar patterns of clonal expansion in carriers
without malignancy [8]. Nevertheless, we recently
demonstrated that the clonal expansion of HTLV-1
positive CD8
+ and CD4
+ lymphocytes relies on two dis-
tinct mechanisms: infection prevents cell death in the
former whereas it recruits the latter into the cell cycle
[8,9]. Indeed, cloned infected but not immortalized CD4
+ T cells from patients without malignancy are cycling
cells that also add up nuclear and mitotic defects typical
of genetic instability, in a Tax dependent manner.
Important and rapid fluctuations in the levels of cell
cycling and apoptosis are the hallmark of normal CD4
+
and CD8
+ cells and lie at the heart of the adaptive
immune response (reviewed in [10]). For example, naive
CD4
+ and CD8
+ T cells specific for a particular antigen
occur at very low frequencies that may be undetectable
in vivo. Upon infection, antigen-specific CD4
+ T cells
can be as many as 1 in 20 in the spleen, and antigen-
specific CD8
+ T cells may be one in two [10]. After this
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reduces the memory cell population to ~5% of the peak
number of responding T cells. Modulation of cell
cycling and apoptosis are the hallmark of HTLV-1 as
several virus-encoded proteins such as Tax, HBZ, p13,
p30 and p12 interfere with cell cycling and/or apoptosis
[11-13]. For example Tax, which is expressed by both
infected CD4
+ and CD8
+ cells, can both stimulate cell
cycling and block apoptosis in transfected or transduced
cells [14-19].
These wide ranges of cellular and viral capabilities,
with regard to cell cycle and apoptosis, contrast with
the archetypal behavior of cloned T cells derived from
naturally infected individuals, which links HTLV-1
infection with CD4
+ cell proliferation and CD8
+ cell
accumulation. Phenotype-specific transcription factor
availabilities have been proposed to explain the different
consequences of virus expression between CD4
+ and
CD8
+ cells [8,9,20]. Alternatively, given the positive and
negative selection forces that act on HTLV-1 replication
throughout the duration of the infection in vivo
(reviewed in [21]), the mechanism underlying the clonal
expansion of CD4
+ and CD8
+ cells might well have
been selected in vivo. Here, we have cloned infected and
uninfected CD4
+ and CD8
+ cells derived from TSP/
HAM patients infected for more than 6 to 26 years, and
we have compared them for viral expression, morpholo-
gical alterations, cell cycle and apoptosis with cells
derived from a recent in vitro infection and cloned in
the same conditions only 1 month after experimental
infection. We show that recent and chronic infections
protect infected CD8
+ cells from cell death while produ-
cing significantly distinct effects on the cell cycle of
CD4
+ and CD8
+ clones, and we provide evidence that
the preleukemic phenotype typical of infected CD4
+
cells has been selected in vivo.
Materials and methods
Ethics statement
This study was conducted according to the principles
expressed in the Declaration of Helsinki. The study was
approved by the Institutional Review Board of the Léon
Bérard anticancer center. All patients provided written
informed consent for the collection of samples and sub-
sequent analysis.
Samples studied
Peripheral blood mononuclear cells (PBMCs) were
obtained after informed consent from 4 patients with
TSP/HAM and from 5 uninfected blood donors. The
HTLV-1-negative acute lymphoblastic leukemia T-cell
line Jurkat and the HTLV-1-transformed T-cell lines
MT4, MT2 and C91PL were propagated as previously
described [22,23].
In vitro infection with HTLV-I
Fresh PBMCs were separated from HTLV-1-negative
donor blood samples by Ficoll (Pancoll, Biotech GmBH)
density gradient centrifugation. HTLV-1 transmission
was performed by co-culturing the PBMCs with lethally
irradiated (60 Gy) HTLV-1-positive MT2 cells at a ratio
of 5:1, as described elsewhere [24]. The MT2 cell line is
known to be chronically infected with HTLV-1 [25].
Co-cultures were maintained for 28 days in six-well
plates in 4 ml of RPMI 1640 medium (Gibco, Paisley,
United Kingdom) containing 100 U/ml of recombinant
interleukin 2 in the absence of exogenous stimulation
such as by phytohemagglutinin (PHA).
T-cell limiting dilution cloning
PBMCs were cloned by limiting dilution (0.1 cell per
well) in Terasaki plates after removal of adherent cells.
The medium used for T lymphocytes was RPMI 1640
containing penicillin and streptomycin, sodium pyruvate,
non-essential amino acid solution, 2-mercaptoethanol,
10% filtered human AB serum and 100 U/mL recombi-
nant IL-2 (Chiron Corporation). For cloning, the med-
ium was supplemented with 1 μg/mL PHA (Abbott
Murex HA 16) and 5 × 10
5/ m Li r r a d i a t e d( 3 0G y )a l l o -
geneic PBMCs (feeder cells). The Terasaki plates were
stored at 37°C for 10 days in aluminium foil, then
checked for growing cells under a microscope. Positive
cultures were transferred to 96-well U-bottom plates in
the medium used for T lymphocytes, then restimulated.
T lymphocytes were restimulated every 14 days with
PHA (1 μg/mL) and fresh feeder cells (10
6/mL). Lethally
irradiated PBMCs from 3 distinct allogeneic, HTLV-I
negative donors were used as feeder cells to exclude the
possibility of clones becoming infected in vitro.T op r e -
serve the original growth characteristics of the cells,
clones were maintained this way for no more than 4
months, after which time a fresh aliquot was thawed.
Phenotypic determination
Antibodies recognizing CD4 and CD8 were purchased
from DakoCytomation. For fluorescence-activated cell
scanner (FACScan) analysis, PBMCs or cloned T cells
were incubated with 5% filtered human serum, then
stained with antibodies. Staining and scanning were per-
formed in phosphate-buffered saline (PBS) with 2% fetal
calf serum (FCS). Isotype-matched controls were used.
Data were acquired on a FACScan and analyzed by
means of the CellQuest™ software (Becton Dickinson).
Apoptosis assay
Apoptosis was assessed using the APOPTEST™ kit
(DakoCytomation) containing fluorescein-conjugated
annexin V, propidium iodide (PI) and binding buffer.
Cells suspended in the binding buffer were mixed with
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ute incubation, cells were analyzed by FACScan. By com-
bining annexin V/FITC and PI, three distinct phenotypes
could be discriminated: unlabeled non-apoptotic live
cells, apoptotic cells labeled by annexin V/FITC, and
necrotic cells (necrosis or late apoptosis) labeled by both
annexin V/FITC and PI. Overall, for each sample ana-
lyzed, this experiment permitted the categorization of the
c e l l sa sv i a b l e( A n n V
-/PI
-), early apoptotic (AnnV
+/PI
-),
late apoptotic (AnnV
+/PI
+) or dead (AnnV
-/PI
+).
Cell cycle analysis
Cell cycle distribution was assessed by measuring the
DNA content of a suspension of fresh nuclei by flow
cytometric analysis after PI staining. Cloned T cells (5 ×
10
5) were washed with PBS. The supernatant was dis-
carded, and cells were permeabilized with 250 μLo f
70% ethanol for 30 minutes at 4°C with rotation. After
ethanol elimination, cells were resuspended in 125 μL
PBS. After storage at 4°C for a few hours, cells (>10,000)
were labeled by PI in the presence of RNase A (Sigma),
scanned by flow cytometry and then analyzed with the
ModFit LT™ software.
Polymerase chain reaction
T-cell clones were screened for HTLV-I proviral DNA
by polymerase chain reaction (PCR) amplification with
LTR-specific primers, as previously described [26].
Inverse PCR (IPCR) amplification of HTLV-1 3’ LTRs
and flanking sequences was carried out on the DNA
extracted from cloned T cells, as previously described
[8]. Expression of tax was quantified by real-time quan-
titative RT-PCR, as described [27]. Analysis of TCR-
gamma chain gene rearrangements was performed on
the DNA extracted from generated clones, as previously
described [28]. This permitted confirmation of the
monoclonality of the corresponding cultured cells. Pro-
ducts from multiplex PCR were run on a denaturating
gradient gel, which enabled the detection of a band and
gave a specific imprint of a given T-cell clone, if the
clone accounted for at least 1% of the total lymphocytes
present in the sample.
Molecular cloning and sequencing
Purified products from IPCR experiments were phos-
phorylated using T4 polynucleotide kinase (Pharmacia,
Uppsala, Sweden), then ligated with SmaI-digested (Phar-
macia) and dephosphorylated M13mp18 replicative form
DNA (New England Biolabs), as previously described
12,32.
After transformation of Escherichia coli XL1 by electro-
poration, recombinant M13 plaques were screened by
hybridization with the HTLV-1 LTR-specific
32P-labeled
oligonucleotide BIO5. Single-stranded templates were
sequenced using fluorescent dideoxynucleotides (Perkin
Elmer). The products were resolved on an Applied Bio-
systems 377A DNA sequencer (Perkin Elmer) with 377A
software (Perkin Elmer). Sequence alignments were per-
formed with the Sequence Navigator Software (Perkin
Elmer).
Results
Figure 1 summarizes the strategy used for comparing
the effects of in vitro infection and persistent in vivo
infection on the behavior of CD4
+ and CD8
+ cells.
T-cell limiting dilution cloning of PBMCs from the 4
TSP/HAM patients allowed us to clone uninfected and
naturally infected CD4
+ and CD8
+ cells from the same
infected individuals [8]. This permitted us to enrich our
previously published library of in vivo derived clones
[8]. PBMCs from Patient 1 have been previously assayed
for clonal expansion and 3’ flanking sequence analyses
on several occasions [4,29-31]. IPCR products from 4
clones generated by limiting dilution cloning of patient
1 PBMCs were sequenced and, for 1 CD4
+ clone, the 3’
provirus integration site sequence matched that identi-
fied in PBMCs collected 7 years earlier (Figure 2). This
indicates that the present cloning strategy allows for the
analysis of in vivo infected and persistently expanded
clones. In vitro HTLV-1 cellular infection was per-
formed herein by co-culturing PBMCs isolated from
healthy adult donors, seronegative for HTLV-1/2, HIV,
HBV, and HCV, with lethally irradiated MT2 [24]. Cells
were next cloned and cultured as PBMCs from HAM/
TSP, and all generated clones were assayed for HTLV-1
infection, tax expression, CD4
+ and CD8
+ expression,
cell cycling and apoptosis, as shown in Figure 1 and as
detailed in the Methods section. Clonal efficiency was
identical for in vivo-a n din vitro- derived cells. Table 1
represents the distribution of analyzed T cell clones
according to the route of infection. All 152 clones har-
bored distinct and unique TCR, as evidenced by multi-
plex PCR-gamma-DGGE [8]. Infected and uninfected
clones were not immortalized and required IL-2 and sti-
mulation with PHA and feeder cells at 14-day intervals
for continued growth. MT2 cells harbor 18 integrated
proviruses per cell [24], and its level of tax expression
was measured as 25274.3 arbitrary units (AU). At day 7
of co-culture of fresh PBMCs with irradiated MT2 cells,
inverse PCR failed to detect any MT2 specific HTLV-1
integration site; at this time point, the proviral copies
detected corresponded to newly infected cells. There-
fore, subsequently cloned CD8
+ and CD4
+ cells corre-
sponded to bona fide newly infected cells in vitro.
Given that tax expression correlates with infected T
cell behavior [14-19], we compared the amounts of tax
transcripts between in vitro and in vivo infected cells.
Figure 3 represents the distribution of tax expression in
the 79 infected CD4
+ and CD8
+ clones. In 7 of the 24
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amount of tax expression was above the detection
threshold: 4/12 CD4
+ (33%) and 3/12 CD8
+ (25%)
clones. In tax positive clones derived from in vitro infec-
tion, the HTLV-1 tax mRNA load ranged from 16.7 to
474.5 AU (mean ± se of mean 114.1 ± 61.0) without sig-
nificant difference between CD4
+ (mean ± se of mean
43.0 ± 11.1) and CD8
+ cells (mean ± se of mean 208.7 ±
134.1). In 50 of the 55 in vivo HTLV-1 infected clones
screened (~91%), the amount of tax expression was
above the detection threshold: 33/36 CD4
+ (91.7%) and
17/19 (89.5%) CD8
+ clones. In these tax positive clones
derived from TSP/HAM, the HTLV-1 tax mRNA load
ranged from 41.5 to 603475.5 AU (mean ± se of mean
139816.0 ± 30965) without significant difference
between CD4
+ and CD8
+ clones. For both CD4
+ and
CD8
+ cells, the frequency of tax positive clones was sig-
nificantly higher in cells derived from in vivo infection
(p = 0.001 for CD4
+ and CD8
+ clones, Fisher exact test)
and the level of tax expression in tax positive clones was
significantly higher in CD4
+ or CD8
+ clones derived
from TSP/HAM than in those generated after experi-
mental infection (p < 10-4 for tax+-CD4
+ clones, p =
0.048 for tax+-CD8
+ clones, Mann Whitney test) (Figure
3). These results indicate that in vitro infection gener-
ates infected CD4
+ and CD8
+ clones exhibiting signifi-
cantly lower amounts of tax mRNA than cloned T cells
from TSP/HAM. This allowed us to conclude that, in
vivo, persistent infection selects tax-expressing clones.
In vivo infection has been found to trigger cellular
morphological changes that depend on the T cell phe-
notype and tax expression [8,9]. Cell morphology was
therefore analyzed in all infected and uninfected clones
a n dc o m p a r e db e t w e e nc e l l sd e r i v e df r o min vivo and
in vitro infections. Clones derived from in vitro infection
did not display significantly different patterns of mor-
phological changes after infection. For CD4
+ clones, the
proportions of multinucleated cells in uninfected versus
infected clones were 0.023% and 0.016%, respectively
[not significant (NS)]. These values were 0.04% and
0.44% for CD8
+ clones (NS), without significant correla-
tion between tax expression and cell morphology. In
Figure 1 Strategy used to compare in vivo and in vitro HTLV-1 infections. The materials used for in vivo infection were PBMCs derived from
TSP/HAM patients with a disease duration of more than 6 to more than 26 years. In vitro infection was carried out by 28-day co-culture of
normal PBMCs from blood donors with irradiated MT2 cells, as detailed in the Methods section. Both cell preparations were cloned at 0.1 cell/
well and cultured during 1.5 – 3 months in the same conditions. Then cells were assayed for HTLV-1 infection and integration, tax expression,
CD4
+ and CD8
+ expression, cell cycling and apoptosis, as shown in Figure 1 and as detailed in the Methods section.
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+ clone. Clone #60 from patient 1 was generated by limiting dilution
cloning of PBMCs collected in 2003. IPCR amplification of the 3’ HTLV-1 flanking sequences, molecular cloning and sequencing permitted the
isolation of a 122 bp integration site that matched the AF228936 sequence previously isolated by sequencing HTLV-1 integration sites in PBMCs
harvested from the same patient in 1996.
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derived from patients with HAM/TSP displayed multi-
nuclearity and impaired cytokinesis, with the presence
of chromatin bridges almost exclusively restricted to
CD4
+ HTLV-1 positive clones and correlated with the
level of tax expression. For example, the proportions of
multinucleated cells in infected versus uninfected cloned
CD4
+ cells derived from TSP/HAM were 2.06%, and
0.05%, respectively (p = 0.01, Mann-Whitney test).
These values were 0.08% and 0.51% for CD8
+ cells (NS).
Multinuclearity correlated with tax expression (R=
0.829, p = 0.002, Spearman rank correlation). These
results indicate that newly in vitro infected CD4
+ lym-
phocytes do not display the typical cellular features of
genetic instability that characterize in vivo infected
CD4
+ clones.
After having characterized in vitro and in vivo infected
clones for tax expression and cell morphology, we next
compared the effects of in vitro and in vivo infections on
the cell cycle. The percentages of MT2 cells in the G0G1,
G2M and S phases of the cycle were respectively 89%, 3%,
and 8%. For all clones, the cell cycle was assessed by flow
cytometry at day 6 following PHA stimulation after 1.5 to
2.5 months of culture (Figure 1), as detailed in the Meth-
ods section. Figure 4A represents fluctuations of cell cycle
distribution for infected or uninfected CD4
+ and CD8
+
clones derived from in vitro versus in vivo infection,
respectively. For the 32 CD4
+ clones derived from in vitro
infection, there was no significant difference in cell distri-
bution across the phases of the cell cycle between
HTLV-1 positive and negative lymphocytes (Figure 4A).
Conversely, cell distribution across the phases of the cell
cycle was significantly different between infected and
uninfected CD8
+ lymphocytes (Figure 2A) cloned after in
vitro infection. Overall, the percentages of CD8
+ lympho-
cytes left uninfected after in vitro infection in the G0G1,
G2M and S phases of the cycle were respectively 86%, 3%,
and 11%, versus 81%, 3%, and 16% for in vitro infected
lymphocytes (p = 0.035 for cells in the S phase, Mann-
Whitney test). There was no correlation between tax
expression and cell distribution across the phases of the
cell cycle for either CD4
+ and CD8
+ clones derived from
in vitro infection. For the 55 infected clones derived from
in vivo persistent infection, i.e. from PBMCs of patients
with HAM/TSP, results of cell cycle analysis paralleled
and even surpassed those previously published [8], with a
significant redistribution of CD4
+ lymphocytes from the
G0/G1 phase towards the S and G2M phases of the cell
cycle (Figure 4A). In contrast, upon in vivo infection, there
was no significant cell cycle alteration for CD8
+ clones.
For infected clones derived from TSP/HAM, the tax
mRNA load correlated negatively with the percentage of
cells in the G0G1 phase of the cycle (p < 10-4, R -0.629,
Spearman rank correlation) and positively with the per-
centage of cells in the G2M and S phases (p = 0.001,
R 0.621, Spearman rank correlation). These results indi-
cate that newly in vitro infected CD4
+ or CD8
+ cells dis-
play cell cycle alterations significantly distinct from those
of chronically infected CD4
+ or CD8
+ cells derived from
TSP/HAM. Figure 4A shows that these differences were
based on significantly distinct cell cycle distributions
between in vitro and in vivo infected clones and, surpris-
ingly, also between uninfected clones derived from in vitro
versus in vivo infection. For infected CD4
+ clones, the
Table 1 Distribution of cloned lymphoid cells according
to HTLV-1 infection
In vitro infection In vivo infection
CD4+ CD8+ CD4+ CD8+
Uninfected 20 20 18 15
Infected 12 12 36 19
Phenotype CD4+ CD8+ CD4+ CD8+
Infection In vitro Invivo
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Figure 3 In vivo CD4
+ and CD8
+ clones are selected for tax expression. Tax gene expression was measured by quantitative RT-PCR as
detailed in the Methods section. Horizontal bars represent the median tax expression level for each category of clones.
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of the cell cycle was significantly lower than that of
infected CD4
+ cells derived from TSP/HAM (3.3 versus
5.9, p < 10
-4, Mann Whitney test) (Figure 4A). On the
contrary, the proportion of cells left uninfected after
in vitro infection and within the S phase of the cell cycle
was significantly higher than that of uninfected CD4
+ cells
derived from TSP/HAM (10.3 versus 5.1, p = 0.004, Mann
Whitney test). For CD8
+ infected clones, the proportion of
cells within the S phase of the cell cycle was significantly
higher in vitro than in vivo (16 versus 11.7, p = 0.04,
Mann Whitney test). There was no significant difference
in cell distribution across the phases of the cell cycle
between in vitro and in vivo infection for uninfected CD8
+
clones. These results indicate that both infected and unin-
fected lymphocytes from chronically infected organisms
HTLV-
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Figure 4 Cell cycling but not cell death is selected during HTLV-1infection in vivo.C D 4
+ and CD8
+ clones (152 clones) were analyzed at
day 6 from PHA stimulation for cell cycle (A) and apoptosis (B). * p < 0.05.
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tinguishing them from newly virus-exposed cells. We con-
clude that persistent in vivo infection selects specific
lymphoid phenotypes with respect to the cell cycle.
For all clones, cell death was assessed by flow cytome-
try at day 6 following PHA stimulation after 1.5 to 2.5
months of culture (Figure 1), as detailed in the Methods
section. For the MT2 cell line, the percentage of apopto-
tic cells was 5.3%. Figure 4B represents fluctuations of
apoptotic cell distribution for infected and uninfected
CD4
+ and CD8
+ clones derived from in vivo versus in
vitro infection, respectively. In contrast to cell cycle ana-
lysis, cell death analysis yielded roughly identical results
for in vitro and in vivo infections (Figure 4B). For CD4
+
clones derived from in vitro or in vivo infection, there
was no significant difference in cell viability, apoptosis
and necrosis (necrosis and late apoptosis), between
HTLV-1 positive and negative lymphocytes. In contrast,
the percentage of apoptotic cells was significantly
decreased in infected CD8
+ cells, both in vitro (6% ver-
sus 19%, p = 0.017, Mann-Whitney test) and in vivo
(10% versus 14.8%, p = 0.048, Mann-Whitney test). The
level of tax expression did not influence apoptosis,
necrosis and cell viability in in vitro or in vivo CD4
+ or
CD8
+ infected clones. For CD4
+ and CD8
+ clones, there
was no significant difference in the proportion of apop-
totic cells between in vitro and in vivo infected or unin-
fected cells. These results indicate that both in vitro and
in vivo infections have the same effect on cell death in
CD4
+ and CD8
+ clones.
Discussion
Our data show that persistent in vivo HTLV-1 infection
selects tax-expressing clones and specific cell behaviors,
with respect to apoptosis and cell cycle. In vitro and
in vivo HTLV-1 infections have significantly distinct
effects on the proliferation, but not on the accumulation
of infected CD4
+ and CD8
+ cells. Regarding the cell
cycle, the known HTLV-1-dependent recruitment of
infected CD4
+ cells into the cell cycle [8] appears
restricted to the persistent infection while in vitro infec-
tion has been found to trigger CD8
+ cell cycling. In con-
trast, regarding apoptosis, the known HTLV-1-
dependent prevention of CD8
+ T cell death appears to
pertain to both in vivo and in vitro infected clones.
These differences indicate that, in chronically HTLV-1
infected patients, infected CD4
+ cells are positively
selected for tax expression and cell cycling whereas
infected CD8
+ cells and uninfected CD4
+ cells are nega-
tively selected for the same processes. Importantly, the
preleukemic phenotype of infected CD4
+ cells has been
found restricted to clones derived from persistently
in vivo infected cells.
Tax combines a positive effect on cell cycle with a
negative effect on apoptosis [14-19]. Furthermore Tax is
the immunodominant target antigen recognized by
virus-specific cytotoxic T lymphocytes (CTLs) (reviewed
in [21]) that kill CD4
+ cells naturally infected with
HTLV-I and expressing Tax in vitro via a perforin-
dependent mechanism [32]. Tax expression has been
found to be influenced by mutations [33], 5’LTR dele-
tion [34] or methylation [35], and integration site posi-
tion [36,37]. Given the cell-associated replication of
HTLV-1, Tax expression appears ambivalent for infected
cells. On the one hand it promotes cell cycling and cell
accumulation and thereby the clonal expansion of
infected cells, whereas on the other hand it exposes
infected cells to CTL-mediated lysis. After limiting dilu-
tion cloning, more than 90% of in vivo derived HTLV-1
positive clones retain the capacity to express tax versus
less than 30% of in vitro generated clones. This selection
of tax positive clones in vivo indicates that the ability to
express tax is crucial for persistent clonal expansion of
infected CD4
+ or CD8
+ cells in vivo.
Prevention of cell death governs the clonal expansion
of infected CD8
+ cells in vivo [8,9]. Here we have found
that HTLV-1 prevents CD8
+ cell death both in vitro and
in vivo (Figure 4), suggesting that this mechanism of
infected CD8
+ clonal expansion does not undergo any
specific selection during chronic infection. In addition,
in vitro infection redistributed CD8
+ lymphocytes from
the G0/G1 phase towards the S phase of the cell cycle
whereas no significant phase distribution difference was
seen between uninfected and infected CD8
+ clones
derived from TSP/HAM. Thus, as CD4
+ cells, CD8
+
cells can be redistributed across the cell cycle upon
infection. This finding rules out the previous assumption
that phenotype-dependent transcription factor availabil-
i t yg o v e r n st h ep h e n o t y p e - s p e c i f i cc o n s e q u e n c e so f
infection on cell cycling [8,9]. However, the cycling of
infected CD8
+ cells is dramatically slowed down in vivo,
towards a cell distribution identical to that of uninfected
cells (Figure 4A). Thus in the present model, HTLV-1
can both stimulate the cell cycle and prevent the cell
death of non-transformed CD8
+ lymphocytes whereas
the clonal expansion of these infected cells remains
restricted to apoptosis inhibition in vivo.T h i si n d i c a t e s
that in vivo,i n f e c t e dC D 8
+ cells are negatively selected
for cell cycling.
For CD4
+ cells, experimental in vitro infection had only
modest effects on cell cycling and apoptosis while our
experiments confirmed and extended the known positive
effect of infection on CD4
+ cell cycling in vivo [8,9]. In
fact for infected CD4
+ clones, the proportion of cycling
cells was significantly higher in vivo than in vitro
whereas, surprisingly, for uninfected CD4
+ clones, this
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From these differences we concluded that in chronically
infected patients, infected CD4
+ cells are positively
selected for cell cycling whereas uninfected CD4
+ cells
are negatively selected for the same process. Like cell
cycling, cellular morphological changes typical of genetic
instability were found restricted to in vivo infected CD4
+
cells, with a statistically significant correlation between
tax expression, cells distribution across the phases of the
cell cycle, and morphological abnormalities. In contrast,
recently in vitro infected CD4
+ cells did not display sig-
nificant morphological changes. Thus the preleukemic
phenotype that characterizes HTLV-1 positive CD4
+ cells
is restricted to in vivo infected cells, meaning that it has
been selected during persistent infection.
Hitherto, two factors have been considered to rule
HTLV-1 replication and pathogenicity: the effects of
HTLV-1 encoded proteins onb o t ht h ev i r u sa n di t s
host cells; and the consequences of the robust anti-
HTLV-1 CTL response, which mainly target Tax-
expressing cells. By showing that uninfected CD4
+ cells
from TSP/HAM are negatively selected for cell cycling,
the present results suggest that additional forces disturb
T-cell homeostasis in infected individuals. Uninfected
CD4
+ cells account for the majority of the T-cell reper-
toire in infected individuals, and their impairment for
cell cycling might be expected to foster immunosuppres-
sion and therefore contribute to leukemogenesis, inflam-
mation, and susceptibility of infected individuals to
certain opportunistic diseases.
In conclusion this work demonstrates that persistent
HTLV-1 infection selects specific lymphoid phenotypes -
including the preleukemic features of tax positive CD4
+
clones,- with respect to cell cycling and that these involve
both infected and uninfected cells. This selection results in
fixed phenotypes, as evidenced after 1.5 to 3 months of
cell culture in vitro. Tax is the main target for the anti-
HTLV-1 cellular immune response (CTL), and tax expres-
sion correlates with cell cycling and cellular morphological
changes. Given that infection selects tax-expressing clones
in vivo, it could be speculated that the CTL response parti-
cipates in the imprinted selection of infected cell cycling -
especially for CD8
+ cells, and thereby in deciding the
mechanism of clonal expansion in vivo. However addi-
tional factors necessarily account for the selection of the
specific phenotype of uninfected clones derived from TSP/
HAM. Whether these patterns of clonal expansion contri-
bute to maintain a normal and constant lymphocyte pool
throughout the infection remains to be elucidated.
Furthermore it will be interesting to test whether the
infection also selects for the expression of additional
HTLV-1 encoded proteins. Finally, as the preleukemic
phenotype characterizing infected CD4
+ cells is restricted
to in vivo derived clones, the present findings suggest that
virus-cell interactions alone are not sufficient for initiating
early leukemogenesis in vivo. This supports the current
limiting dilution cloning strategy as an appropriate tool for
investigating HTLV-1-associated oncogenesis in naturally
infected cells.
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